# tables/efficacy/dort01.qmd result_v1 development

    Code
      print(data_snap[[i]])
    Output
                                                  A: Drug X    B: Placebo   C: Combination
                                                   (N=134)      (N=134)        (N=132)    
      ————————————————————————————————————————————————————————————————————————————————————
      Responders                                      68           73             62      
        Responders with subsequent event (%)      46 (67.6%)   39 (53.4%)     32 (51.6%)  
          Earliest contributing event                                                     
            Death                                     26           24             16      
            Disease Progression                       20           15             16      
        Responders without subsequent event (%)   22 (32.4%)   34 (46.6%)     30 (48.4%)  
      Duration of response (Months)                                                       
        Median                                       5.3          6.2            5.3      
          95% CI                                  (4.6, 5.8)   (5.4, 6.3)     (4.6, 5.8)  
        25% and 75%-ile                            3.8, 6.3     4.6, 6.4       4.0, 6.1   
        Range                                     0.5 to 6.4   0.9 to 6.5     0.6 to 6.6  
      12 Months duration                                                                  
        Patients remaining at risk                    NA           NA             NA      
        Event Free Rate (%)                           NA           NA             NA      
        95% CI                                        NA           NA             NA      

# tables/efficacy/dort01.qmd result_v2 development

    Code
      print(data_snap[[i]])
    Output
                                                  A: Drug X     B: Placebo    C: Combination
                                                   (N=134)       (N=134)         (N=132)    
      ——————————————————————————————————————————————————————————————————————————————————————
      Responders                                      68            73              62      
        Responders with subsequent event (%)      46 (67.6%)    39 (53.4%)      32 (51.6%)  
          Earliest contributing event                                                       
            Death                                     26            24              16      
            Disease Progression                       20            15              16      
        Responders without subsequent event (%)   22 (32.4%)    34 (46.6%)      30 (48.4%)  
      Duration of response (Months)                                                         
        Median                                       5.3           6.2             5.3      
          95% CI                                  (4.6, 5.8)    (5.4, 6.3)      (4.6, 5.8)  
        25% and 75%-ile                            3.8, 6.3      4.6, 6.4        4.0, 6.1   
        Range                                     0.5 to 6.4    0.9 to 6.5      0.6 to 6.6  
      Unstratified Analysis                                                                 
        p-value (log-rank)                                        0.0223          0.6659    
        Hazard Ratio                                               0.60            0.90     
        95% CI                                                 (0.39, 0.93)    (0.57, 1.44) 

# tables/efficacy/dort01.qmd result_v3 development

    Code
      print(data_snap[[i]])
    Output
                                                  A: Drug X    B: Placebo   C: Combination
                                                   (N=134)      (N=134)        (N=132)    
      ————————————————————————————————————————————————————————————————————————————————————
      Responders                                      68           73             62      
        Responders with subsequent event (%)      46 (67.6%)   39 (53.4%)     32 (51.6%)  
          Earliest contributing event                                                     
            Death                                     26           24             16      
            Disease Progression                       20           15             16      
        Responders without subsequent event (%)   22 (32.4%)   34 (46.6%)     30 (48.4%)  
      Duration of response (Months)                                                       
        Median                                       5.3          6.2            5.3      
          90% CI                                  (4.6, 5.8)   (5.5, 6.3)     (4.6, 5.7)  
        25% and 75%-ile                            3.8, 6.3     4.6, 6.4       4.0, 6.1   
        Range                                     0.5 to 6.4   0.9 to 6.5     0.6 to 6.6  
      12 Months duration                                                                  
        Patients remaining at risk                    NA           NA             NA      
        Event Free Rate (%)                           NA           NA             NA      
        97.5% CI                                      NA           NA             NA      

# tables/efficacy/dort01.qmd result_v4 development

    Code
      print(data_snap[[i]])
    Output
                                                    A: Drug X        B: Placebo     C: Combination
                                                     (N=134)          (N=134)          (N=132)    
      ————————————————————————————————————————————————————————————————————————————————————————————
      Responders                                        68               73               62      
        Responders with subsequent event (%)        46 (67.6%)       39 (53.4%)       32 (51.6%)  
          Earliest contributing event                                                             
            Death                                       26               24               16      
            Disease Progression                         20               15               16      
        Responders without subsequent event (%)     22 (32.4%)       34 (46.6%)       30 (48.4%)  
      Duration of response (Months)                                                               
        Median                                         5.3              6.2              5.3      
          95% CI                                    (4.6, 5.8)       (5.4, 6.3)       (4.6, 5.8)  
        25% and 75%-ile                              3.8, 6.3         4.6, 6.4         4.0, 6.1   
        Range                                       0.5 to 6.4       0.9 to 6.5       0.6 to 6.6  
      6 Months duration                                                                           
        Patients remaining at risk                      10               18               7       
        Event Free Rate (%)                           33.46            50.23            30.56     
        95% CI                                    (20.88, 46.05)   (36.54, 63.92)   (13.56, 47.57)

